US-based Pfizer Inc. (NYSE: PFE) reported Q2 2025 financial results, revealing a 10% year-on-year (YOY) increase in operational revenues to USD 14.7 billion. Over the first half of 2025, sales were up 1% YOY to USD 28.37 billion. Global biopharmaceutical sales accounted for USD 14.3 billion of the Q2 revenue.
CEO Commentary
CEO Dr. Albert Bourla expressed satisfaction with the strong quarterly performance. Pfizer maintained its full-year revenue guidance at USD 61.0-64.0 billion and raised its earnings per share (EPS) forecast by 10 cents to USD 2.90-3.10.
Business Unit Performance
- Primary Care: Grew by 12% YOY to USD 5.54 billion, driven by strong demand for COVID-19 products Paxlovid and Comirnaty.
- Specialty Care: Increased by 7% to USD 4.38 billion.
- Oncology: Rose by 11% to USD 4.39 billion.
Product Highlights
- Paxlovid and Comirnaty: Grew by 71% and 95% respectively to USD 427 million and USD 381 million.
- Eliquis (apixaban): Expanded by 6% to USD 2 billion, co-marketed with Bristol Myers Squibb (BMS).
- Vyndaqel (tafamidis): Grew by 21% globally to USD 1.615 billion in sales.
- Padcev (enfortumab vedotin): Increased by 38% to USD 542 million.
Earnings Call Highlights
- R&D and Commercial Execution: CEO Bourla emphasized Pfizer’s focus on R&D productivity and commercial execution. He highlighted the performance of recently launched Elrexfio (elranatamab), a BCMA-targeted T-cell engager for multiple myeloma, which generated USD 85 million in revenue.
- Pipeline Progress: Bourla pointed to the potential of the first-in-class integrin-beta 6 (IB6)-targeted antibody drug conjugate (ADC) sigvotatug vedotin, which is in development for non-small cell lung cancer (NSCLC).
- Strategic Partnership: The May 2025 partnership with 3SBio was highlighted as a potential USD 6 billion deal, providing ex-China access to the PD-1-VEGF bispecific PF-08634404, targeting the USD 55 billion PD-1 immunotherapy market.-Fineline Info & Tech
